Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
NCT00344110 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 768
Last updated 2016-11-18
Summary
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
Conditions
Interventions
- DRUG
-
Aliskiren
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals, Japan · Novartis Pharmaceuticals, Japan
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-06-30
- Primary Completion
- 2007-04-30
- Completion
- 2007-04-30
Countries
- Japan
More Related Trials
-
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
NCT00219128 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
NCT00219167 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
NCT01113047 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
NCT00765947 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
NCT00706134 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
NCT01237223 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
NCT00219050 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
NCT00654875 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
NCT00343551 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
NCT00219024 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
NCT00219154 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
NCT00441064 ·Status: COMPLETED ·Phase: PHASE4
-
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
NCT06500689 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
NCT00219180 ·Status: COMPLETED ·Phase: PHASE3
-
New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering
NCT01609959 ·Status: COMPLETED ·Phase: PHASE4
-
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
NCT00260923 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
NCT00294710 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
NCT00705575 ·Status: COMPLETED ·Phase: PHASE3
-
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
NCT01151410 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
NCT00739973 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
NCT00097955 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
NCT00819767 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
NCT00219115 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
NCT01042392 ·Status: COMPLETED ·Phase: PHASE4